Products

PayLink

Create a link. Get paid.

paylink.systems Creator Economy & Community / Creator Storefronts & Link-in-Bio

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Usage-based
No monthly subscription pricing
Creators
Farqan Iqbal
@paylinksystems· 8 followers
Launched
7mo ago
2026-04-21 · Est.

Traffic

Last 12 months
Monthly visitsData through Oct 2026
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
X accounts@paylinksystems
  • Launched on Product HuntLaunch

    Sell any digital product in 30 seconds, keep 97%

    Apr 21 · 7mo agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

  • Direct36%
  • Organic Search30%
  • Referrals14%
  • Social7%
  • Other14%

Countries

  • United Kingdom100%

Search

Domain authority —Domain registered 2026-04-16

KeywordMonthly volume
stripe link21.5K
paylink2,900

Traffic data: Vaneform

Pricing

One Simple Plan
3%per sale
Unlimited payment links

Trial: None · Observed 2026-11-07 · Source page

Pages & changes

Tracked since 2026-04-21

Key pages

Weekly snapshots
Home
paylink.systems/ Snapshot 2026-11-07

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does PayLink cost?
One Simple Plan: 3%per sale. Observed 2026-11-07. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does PayLink get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is PayLink and what platforms does it support?
PayLink is catalogued under Creator Storefronts & Link-in-Bio: Create a link. Get paid.. Supported platforms: Web.

Related products in this category

Creator Economy & Community / Creator Storefronts & Link-in-Bio

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.